A wound-healing response that has gone wrong
For decades, rheumatoid arthritis has been framed as a story of immune aggression — the body attacking itself in a cycle of inflammation and destruction. Researchers at Hospital for Special Surgery have now revealed a quieter, parallel story unfolding inside damaged joints: a misdirected healing process, driven by specialized immune cells, that builds destructive tissue through pathways medicine has largely overlooked. The discovery invites a rethinking of what it means to treat not just the fire of disease, but the misguided architecture the body erects in its wake.
- A population of immune cells called SPP1ʰⁱmacrophages has been caught orchestrating abnormal joint tissue growth in rheumatoid arthritis — operating outside the inflammatory pathways that current drugs are designed to suppress.
- These cells cluster around fibrin scaffolds in the joint lining, dissolve them enzymatically, and then trigger structural cells to multiply — a wound-healing response that has turned relentlessly destructive.
- The tissue expansion this drives, including the invasive pannus that erodes cartilage and bone, has remained largely invisible to researchers focused on immune activation rather than dysregulated repair.
- IL-6-targeting therapies already in use may be working partly by disrupting this remodeling mechanism — a clue that more precise drugs aimed directly at these macrophages could halt joint destruction more effectively.
- The same fibrin-based remodeling pathway appears active in lung disease, lupus, and certain cancers, suggesting this discovery reaches well beyond arthritis into a broader class of conditions where the body's repair systems go wrong.
Rheumatoid arthritis has long been understood as a disease of inflammation — the immune system attacking the joint lining until bone and cartilage erode. But researchers at Hospital for Special Surgery have identified something else happening inside those damaged joints: a coordinated process of abnormal tissue growth that operates largely independent of the inflammatory cascade doctors have spent decades learning to suppress.
The discovery centers on a specialized immune cell population called SPP1ʰⁱmacrophages. Using spatial transcriptomics to map human tissue samples, the HSS team found these cells clustering in fibrin-rich regions of the synovium, the membrane lining the joints. Fibrin normally serves wound repair, but here it functions as a temporary scaffold for something more troubling: the macrophages break it down enzymatically, then stimulate nearby fibroblasts to multiply and expand — driving the excessive tissue growth, including invasive pannus, that destroys cartilage and bone.
Senior author Dr. Laura Donlin describes this as "pro-generative" tissue remodeling — distinct from fibrotic diseases like pulmonary fibrosis, which involve dense collagen buildup, and distinct from classical inflammation. What emerges instead is a hybrid process, part immune activation and part aberrant healing, that has remained largely invisible to a field focused on suppressing immune responses.
The findings also shed light on why existing treatments work. IL-6 signaling, already targeted by several approved RA drugs, appears to sustain these macrophages and their remodeling activity — suggesting those therapies may succeed partly by interrupting tissue growth, not just inflammation. More targeted drugs designed to disrupt SPP1ʰⁱmacrophage function or their interaction with fibroblasts could offer a more direct path to halting joint destruction.
The implications reach further still. Similar cell populations and fibrin-based remodeling have been implicated in interstitial lung disease, lupus, certain cancers, and traumatic injury — suggesting the HSS team has mapped a fundamental mechanism by which the body's repair systems can become pathological across a wide range of conditions.
Rheumatoid arthritis has long been understood as a disease of inflammation—the immune system attacking the joint lining, causing pain and swelling that eventually erodes bone and cartilage. But researchers at Hospital for Special Surgery have now identified something else happening inside those damaged joints: a coordinated process of abnormal tissue growth that operates largely independent of the inflammatory cascade doctors have spent decades learning to suppress.
The discovery centers on a specialized population of immune cells called SPP1ʰⁱmacrophages. Using advanced spatial transcriptomics to map human tissue samples, the HSS team found these cells clustering in specific regions of the synovium—the membrane lining the joints—where they congregate around fibrin, a protein normally involved in blood clotting and wound repair. The fibrin appears to function as a temporary scaffold, and within these fibrin-rich niches, something unexpected unfolds.
The macrophages break down the fibrin through enzymatic activity, then stimulate nearby fibroblasts—the structural cells responsible for building connective tissue—to multiply and expand. This process drives excessive tissue growth in the joint, including the formation of pannus, the invasive tissue that erodes cartilage and bone. What makes this finding significant is that it occurs through pathways distinct from the inflammatory mechanisms that current therapies target. The tissue is growing not because of unchecked immune activation, but because of dysregulated repair processes—essentially, a wound-healing response that has gone wrong.
Dr. Laura Donlin, senior author of the study published in Science Translational Medicine, describes this as "pro-generative" tissue remodeling. The distinction matters. While the SPP1ʰⁱmacrophages resemble immune cells found in fibrotic diseases like pulmonary fibrosis or cirrhosis, the rheumatoid joint environment lacks the dense collagen accumulation that characterizes those conditions. Instead, what emerges is a hybrid process—part inflammation, part aberrant healing—that has remained largely invisible to researchers focused on suppressing immune activation.
The research also illuminates why certain existing treatments work. IL-6 signaling, a pathway already targeted by several approved RA drugs, appears to sustain these macrophages and their tissue-remodeling activity. This suggests that IL-6-targeting therapies may be particularly effective precisely because they interrupt this tissue growth mechanism, not just the inflammatory one. But the findings point toward a broader therapeutic opportunity: drugs designed specifically to disrupt SPP1ʰⁱmacrophage function or their interaction with fibroblasts could offer a more direct approach to halting the abnormal tissue expansion that drives joint destruction.
The implications extend beyond rheumatoid arthritis. Similar immune cell populations and fibrin-based remodeling processes have been implicated in interstitial lung disease, lupus, certain cancers, and even traumatic injury. The pathway the HSS team has mapped may represent a fundamental mechanism by which the body's repair systems can become pathological—a finding that could reshape how researchers approach not just autoimmune disease, but a range of conditions where tissue growth spirals out of control.
Notable Quotes
Rheumatoid arthritis is not only driven by inflammation, but also by dysregulated tissue repair processes. We are seeing a coordinated interaction between immune cells, structural cells, and the extracellular matrix that fuels abnormal growth.— Dr. Laura Donlin, senior author, Hospital for Special Surgery Research Institute
Current treatments focus on suppressing inflammation, but our findings point to additional pathways that drive disease progression. Targeting these tissue remodeling processes could open the door to more precise and effective therapies.— Dr. Laura Donlin
The Hearth Conversation Another angle on the story
So if inflammation isn't the whole story, why have we been treating RA as an inflammatory disease for so long?
Because inflammation is real and it's destructive—it's just not the only engine driving the disease. The tissue growth happens alongside inflammation, and until now, we didn't have the tools to see it clearly. The macrophages are there, the fibroblasts are proliferating, but it looks different from classic inflammation under a microscope.
These SPP1ʰⁱmacrophages—are they the enemy, or are they doing something the body actually needs?
That's the crucial question. In normal wound healing, these cells and this fibrin scaffold are essential. The problem in RA is that the process never stops. It's like the joint is stuck in repair mode, constantly trying to rebuild tissue that's being destroyed, and that cycle itself becomes destructive.
If IL-6 drugs already work, and they target this pathway, does that mean we've been accidentally hitting the right target?
Partially. IL-6 drugs suppress inflammation broadly, and they do help many patients. But they're not perfectly effective for everyone. The new understanding suggests we could design drugs that specifically block the tissue remodeling without necessarily suppressing all inflammation—potentially offering better outcomes with fewer side effects.
What happens if you could stop these macrophages from activating the fibroblasts?
That's the therapeutic frontier. You'd theoretically halt the abnormal tissue growth while potentially preserving the joint's ability to repair itself normally. It's a much more precise intervention than current broad-spectrum anti-inflammatory approaches.
And this mechanism—it shows up in other diseases too?
Yes. Lung disease, lupus, cancer. Anywhere the body's repair machinery gets stuck in overdrive. Understanding it in RA might unlock treatment strategies across multiple conditions.